Navigation Links
Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos Biotechnology AG (SWX:CYTN) announced today results from a phase IIa study with CYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is an immunotherapeutic product candidate currently in development for the treatment of allergic diseases. The present study aimed to assess safety, tolerability and exploratory efficacy of the product candidate in a new indication, namely atopic dermatitis. The study was designed as a placebo-controlled, randomized and double-blind trial in 36 patients suffering from mild to moderate atopic dermatitis (AD). Exploratory efficacy was determined according to the Eczema Area and Severity Index (EASI), a commonly applied test to assess the extent and severity of AD.

Treatment with CYT003-QbG10 was safe and generally well tolerated. In both the placebo-treated and CYT003-QbG10-treated groups a similar reduction of the EASI scores was measured over the study period indicating no treatment effect for CYT003-QbG10 in atopic dermatitis at the dose level tested in this trial.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented: “While CYT003-QbG10 has shown strong efficacy in conjunction with a specific allergen in patients with house dust mite allergy, we are still in the process of identifying the best treatment parameters for its application as a monotherapy. This monotherapy has achieved first promising results in grass pollen and also house dust mite allergy. For the latter indication we are now testing higher doses of the product candidate. Based on the outcome of these studies we will then also consider the path forward in atopic dermatitis.”

About the phase IIa study
The randomized, double-blind and placebo-controlled phase IIa study included 36 male and female patients aged 18 to 65 and suffering from mild to moderate AD. Upon entry into the study, the extent and severity of the disease was assessed by the Eczema Area Severit
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:9/20/2014)... , Sept. 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ... all lots of its Mylan-Nitro Spray 0.4 mg/metered dose due ... of the pump component. A missing "dip ... nitroglycerin to the patient. This defect may lead patients to ... are unable to access it. Not receiving nitroglycerin could place ...
(Date:9/19/2014)... 2014 Medical science liaisons (MSLs) play ... opinion leaders (KOLs) who can provide essential insights ... nature of the MSL function, the changing regulatory ... landscape for creating and maintaining KOL and physician ... oversight responsibility for the MSL function is increasingly ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014 ... claims against the board of directors of PDL BioPharma, ... ) concerning whether the board has breached its fiduciary ... On September 16, 2014, the Company disclosed: ... its independent registered accounting firm, Ernst & Young LLP ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: AEN ... system diseases, announced today that it has executed an agreement ... at approximately $2.0725 per share to a new institutional investor ... proceeds. The investor will also receive warrants to purchase approximately ...
... Graymark Healthcare Inc. (NASDAQ: GRMH ), ... and an innovator in comprehensive care for obstructive sleep ... resupply shipments in the first quarter of 2011.  Resupply ... in what is typically the slowest quarter of the ...
Cached Medicine Technology:Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3Graymark Resupply Orders Reach Record Levels in Q1 2011, Up 107% Year-Over-Year 2Graymark Resupply Orders Reach Record Levels in Q1 2011, Up 107% Year-Over-Year 3
(Date:9/20/2014)... News) -- As flu season approaches, the best way ... a flu shot and a checkup, according to an ... can vaccinate people against the flu, and also address ... stores may provide flu shots for their customers, but ... Parada, medical director of infection prevention and control for ...
(Date:9/20/2014)... 20, 2014 As concerns surrounding ... in gynecological surgeries continue to grow, Bernstein ... announced plans to end coverage for uterine morcellation. ... last month, Harrisburg, Pennsylvania-based Capital BlueCross will end ... The insurer said its decision was prompted by ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee and ... re-visiting that advice and changing his stance after considering two ... on oral health. “There’s good news and great news,” says ... in protecting against gum disease, and red wine can help ... from the September 2014 issue of Boston University School ...
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Earlier this ... their customers may have had their credit card information pilfered ... year, spawning a slew of headline articles like this ... weren’t the only eye opening numbers. , “Most people ... stolen, almost like it’s a way to score a game,” ...
(Date:9/20/2014)... September 20, 2014 The Arizona Advanced ... (MCC) is celebrating National Manufacturing Day by opening its ... machining, processing and additive manufacturing labs will be offered ... 2014 at MCC’s Southern and Dobson campus (1833 W. ... southeast Lot D. , The AzAMI at MCC was ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... up a big sweat to reap the healing benefits ... low-intense exercise program can reduce depression symptoms and boost ... "The power of physical activity to raise the spirits ... Heart and Stroke Foundation researcher Dr. Jocelyn Harris told ...
... German researchers reported that alcohol consumption and cigarette smoking ... in high school students. Coffee drinking and physical inactivity ... the first to investigate modifiable risk factors for different ... early in Headache , a journal published by ...
... of Public Health (HSPH) have found that children and ... promoting smoke-free public places have significantly lower levels of ... living in counties with no smoke-free laws. The ... smoke-free laws had 39% lower prevalence of cotinine in ...
... in the department of biochemistry and organic chemistry at ... year,s recipient of the Georg Charles de Hevesy Nuclear ... profession. Lngstrm was presented the award by SNMan international ... 5𔃇, in Salt Lake City, Utah. In ...
... ... 26th of June 2010. The funds will go to the charities of Live and Cudeca. ... (PRWEB) June 5, 2010 -- On June ... the 4B business networking group a charity skydiving event in Seville. , , ,The collected funds ...
... The combination of two different chemotherapies and a previously ... effective against advanced melanoma, according to results disclosed in ... of the American Society of Clinical Oncology (ASCO) in ... important about the treatment of melanoma," said John M. ...
Cached Medicine News:Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 2Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 3Health News:Alcohol use and smoking are associated with headaches in high schoolers 2Health News:Smoke-free air laws effective at protecting children from secondhand smoke 2Health News:Bengt Roland Långström receives SNM's 2010 Georg Charles de Hevesy Nuclear Pioneer Award 2Health News:Combination treatment regimen not effective against advanced melanoma 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: